CoChat

Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.

Open access
Makis, William, Baghli, Ilyes, Martinez, Pierrick · 2025 · Case Reports in Oncology

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index; 10 of the 14 sources its claims cite were checked for support.

Abstract

Case series of three advanced cancer patients self-administering fenbendazole.

Overview

CoChat Summary

TL;DR

This is a 3-patient case series describing self-administration of fenbendazole (FBZ) in advanced breast cancer, prostate cancer, and melanoma. The authors report complete remission in 2 patients and near-complete remission in 1 patient, but they emphasize that causality cannot be established from these uncontrolled observations.

Key findings

  • Three patients with advanced malignancy (breast, prostate, melanoma) self-administered FBZ and all were reported to tolerate it without adverse effects attributable to FBZ.
  • Case 1 (stage IV breast cancer): after starting FBZ 222 mg/day on November 22, 2021, CA 27.29 fell from 316 to 36.6 by July 2022; a PET scan on April 20, 2022 showed no abnormal metabolic activity, and the patient was deemed in complete remission in June 2022 and remained recurrence-free nearly 3 years later.
  • Case 2 (recurrent stage IV prostate cancer): FBZ 222–444 mg/day started in December 2021 alongside androgen deprivation therapy; after 1 year lymph node involvement had fully resolved, after 2 years imaging showed significant regression with no new metastatic sites, PSA stayed undetectable for over 2 years (<0.05 ng/mL), and the patient remained in near-complete response after 26 months.
  • Case 3 (BRAFV600-mutated stage IIIC melanoma): FBZ 222–444 mg/day began in mid-December 2023; Signatera dropped from 123.37 pre-FBZ to 0.38 by January 17, 2024 and to 0 by February 21, 2024, with “no evidence of disease” reported at February 2024 follow-up and recurrence-free status over 11 months.

Methods

  • Case series design based on 3 patients with advanced cancer who self-administered FBZ outside a regulated clinical trial setting; the report follows the CARE checklist.
  • Data came from clinical records, imaging, laboratory/tumor marker results, and follow-up ranging from 11 months to nearly 3 years.
  • The analysis is descriptive, comparing pre- and post-FBZ clinical course, imaging, and biomarkers; no control group or inferential statistical analysis is reported.

Limitations

  • Stated in the paper: the authors explicitly note the small sample size, retrospective nature, self-selection bias, combination with other treatments, observational design, and inability to establish a causal relationship between FBZ and remission.
  • Stated in the paper: all three patients initiated FBZ on their own, without medical recommendation or prescription, and dosing/monitoring occurred outside regulated clinical settings.
  • Evident from the text: outcomes are confounded by concurrent therapies (for example, hormonal therapy, radiation, and limited immunotherapy), so the independent effect of FBZ cannot be isolated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1159/000546362This paper is marked retracted.

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

5 Valid · 1 Not valid · 2 Not checked · 20 Own results and interpretations

13 more claims

Create a free account to see all 28 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 6
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Citations

Cites

Cited by

See all 1

Metadata

Authors
Makis, W., Baghli, I., & Martinez, P.
Affiliations
Alberta Health Services (CA)
Venue
Case Reports in Oncology
Publisher
S. Karger AG
Published
2025-05-26
Volume
18
Issue
1
Pages
856-863
ISSN
1662-6575 (ISSN-L)
OpenAlex
W4410772980
Cited by
1
References
9
Citations by year
2025: 1
FWCI
0.30
Type
journal article
Language
en
Status
Retracted
Open access
Licence
Locations
  • Case Reports in Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
  • Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Keywords
fenbendazole, anticancer drug repurposing, antiparasitic drugs, self-administration, metastatic cancer, breast cancer, prostate cancer, melanoma, complete remission, tumor regression, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.